SCROLL

PICKING UP THE MOST DIFFICULT FIGHT

At Onegene, we aim to tackle the toughest challenges of curing complex diseases.  With an understanding of the desperation of patients, we focus our efforts on the most pressing needs.  We believe that the next big step in treating complex, untreatable diseases will come from multi-modality drugs.  These drugs are designed to modulate multiple signals in the disease micro-environment,  providing a more comprehensive and surgical approach to treatment. 

PLATFORM

Innovation to speed multi-targeting drug to patients.

UniStac®

Enzyme-mediated protein-protein conjugation technology.

  • Platform 01
    FAST DEVELOPMENT

    No need to optimize heterodimerization.

  • Platform 02
    TRUE PLUG-AND-PLAY

    No limitation of choosing modalities.

  • Platform 03
    MANU- FACTURABILITY

    High production yield for multispecifics.

PIPELINE 01

Liver-directed for multi-targeting drug for advanced liver fibrosis.

OGB21502

Tetra-specific treatment for non-alcoholic steatohepatitis (NASH) by simultaneously addressing metabolic syndrome and inhibiting NLRP3 inflammasome activation.

PIPELINE 02

Enhanced tumor microenvironment immune-activating drug for anticancer therapy.

OGB23501

Tri-specific approach for promoting T-cell based immune activation to efficiently regulate the tumor microenvironment (TME).

NEWS & NOTICE

CAREERS

Driving innovation at multi-target therapeutics.